Company intelligence / Profile preview

Thymon

Ownership: Private
Development stage: Other

Overview

Thymon, LLC has developed two investigational drugs targeting the HIV Tat protein for the treatment of HIV infections. BI‑201 reached clinical development but was discontinued. TUTI‑16 completed a Phase 1/2 trial in asymptomatic, well-controlled HIV patients and its status remains pending further development. There are no approved products.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

TUTI-16

Beyond the preview

Go deeper on Thymon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thymon.

Explore the full profile